Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

Polyethylene glycol 3350 without electrolytes for treatment of childhood constipation

Seen Chung, Adam Cheng and Ran D. Goldman
Canadian Family Physician May 2009; 55 (5) 481-482;
Seen Chung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Cheng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran D. Goldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rgoldman@cw.bc.ca
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

ABSTRACT

QUESTION I have come across many pediatric patients with functional constipation. Is polyethylene glycol 3350 without electrolytes a safe and effective long-term treatment option for these patients?

ANSWER Functional constipation is a common and often difficult problem for parents and families to deal with. Polyethylene glycol 3350 is a safe and effective long-term laxative in pediatric populations, but there are limited studies for its use in children younger than 2 years of age.

Constipation is the most common cause of abdominal pain in the pediatric population.1 It is the cause of an estimated 3% to 5% of pediatric visits to physicians, with up to one-third of children between 6 and 12 years of age reporting constipation at least once a year.2 Up to 95% of children referred for evaluation of constipation have no underlying pathologic condition and receive a diagnosis of functional constipation.2 Despite the scope of this problem, many of the conventional treatments for functional constipation are variably effective and have potential adverse effects, leading to repeat visits to the doctor’s office.3 Lactulose, one of the more commonly used osmotic laxatives, can produce a large amount of gas as a result of bacterial fermentation, which can cause bloating and abdominal pain. Mineral oil, usually given as a lubricant to help passage of hard stool, is associated with aspiration and lipoid pneumonia.3 Enemas using phosphate, mineral oil, or normal saline are effective in relieving rectal disimpaction, but carry the risk of mechanical trauma upon administration and are not recommended for repeated use in the pediatric population.

Polyethylene glycol (PEG) 3350 solution without added electrolytes is an odourless osmotic laxative, which, unlike other colonic lavage solutions, carries no risk of salt absorption and hence no risk of electrolyte imbalance.4 Provided in powder form, this chemically inert substance has very little grit when mixed with juice or water and is absorbed only in trace amounts from the gastrointestinal tract.5

Disimpaction

In a prospective, double-blind, parallel study, Youssef et al4 randomized 40 children between 3 and 18 years of age into 4 groups; each group used different doses of PEG 3350 daily (0.25 g/kg/d, 0.5 g/kg/d, 1.0 g/kg/d, or 1.5 g/kg/d) for 3 days to a maximum of 100 g per day. This study showed that after 3 days of treatment with PEG 3350, 95% of children who used the higher doses (1.0 to 1.5 g/kg/d) became disimpacted, while only 55% of those who used the lower doses (0.25 to 0.5 g/kg/d) became disimpacted. Plasma electrolytes were unchanged in the children of the 2 groups receiving the higher doses of PEG. Although adverse events included flatulence or bloating (18%), loose stools (13%), nausea (5%), vomiting (5%), and pain or cramping (5%), all the children in the study said they would take another 3-day course of PEG 3350 to treat any future fecal impaction.

Maintenance and treatment

There is a growing body of literature to support the efficacy and safety of PEG 3350 in the treatment of children with a diagnosis of functional constipation. Most studies start with 2 years of age as the lower age limit,6–8 but some use 4 years of age as the lower age limit.9,10 Multiple studies have shown that PEG is effective at increasing the number of bowel movements per week, decreasing the straining associated with bowel movements, as well as softening the consistency of the stool.6,7,9–11 The effects of PEG have been shown to start within the first week of treatment9 and can still be seen for up to 30 months after treatment has started, with no change in the effectiveness of PEG.6 The starting dose for the use of PEG as a long-term laxative seems to be between 0.4 and 0.8 g/kg/d, as either a single or twice daily dose.6,9–11 This dose can be tailored to effect for each patient during treatment, with a range of concentrations being used: one study stated a range of 0.27 to 1.4 g/kg/d,11 and another showed a similarly wide range of 0.3 to 1.8 g/kg/d.6 By altering the doses during treatment, parents, with the advice of physicians, were also able to decrease the minor adverse effects of diarrhea, bloating, cramping, and gas, all of which were associated with the use of PEG.8,9,11 The maximum daily dose recorded in these studies was 51 g/d, although the length of treatment at this dose was not described.8

Safety

The safety profile of PEG as a laxative has been reported in various journals12,13; 2 long-term studies included blood-work.8,10 In a prospective observational study of 83 children receiving PEG for 3 to 30 months,8 the test results for hemoglobin, hematocrit, serum electrolyte, blood urea nitrogen, creatinine, and albumin levels and osmolality were normal in all patients who had bloodwork done. Although there were slightly elevated alanine aminotransferase (ALT) levels at first, they resolved by 8 weeks in all but 1 of the patients. Three patients had slightly elevated aspartate aminotransferase (AST) levels (all < 1.5 times normal); however, their AST levels returned to normal while still receiving PEG. In another study,10 30 of the 39 children randomized to receive PEG had bloodwork results; these revealed very mildly elevated platelet counts in 4 children and mildly elevated AST and ALT levels in 2 children. Follow-up plasma electrolyte levels were normal for all. Repeat bloodwork results while taking PEG showed that all AST and ALT values became normal and only 1 of the 4 children continued to have a mildly elevated platelet count. One child was allergic to PEG (ie, skin rash), but all children continued to grow in height and weight over the 12-month course of the study.

Infants and toddlers

Recent retrospective chart reviews have shown that PEG can be effective, safe, and well tolerated in children younger than 2 years of age.5,14,15 The length of treatment was variable (3 weeks to 21 months15 and 1 to 37 months5), but all outcomes showed that PEG was safe and effective as a long-term laxative. The long-term doses of PEG varied (0.3 to 2.1 g/kg/d,5 0.4 to 1.9 g/kg/d,14 or 0.26 to 1.26 g/kg/d15); however, the mean effective dose of 0.8 to 1.0 g/kg/d was similar in all these studies. The minor adverse effects of increased gas and diarrhea could be decreased with a decrease in the dose of PEG.5,15 No child refused PEG.5,14 All bloodwork results, including complete blood count, electrolyte level, renal function, and liver function, were within normal limits for those children tested.5 One of the limitations of these studies is the small sample size for children younger than 1 year old.

Conclusion

Polyethylene glycol 3350 without electrolytes is a safe, effective, and well-tolerated option for treatment of constipation in children. A 3-day course of PEG 3350 at a dose of 1.0 to 1.5 g/kg/d can be used for fecal disimpaction. For maintenance therapy, a starting dose of 0.4 to 0.8 g/kg/d can be initiated then titrated to maximum, depending on effectiveness of therapy and severity of side effects. Parents should be educated about potential rare side effects, including flatulence, loose stool, nausea, vomiting, and abdominal cramping.

PRETx

Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program at the BC Children’s Hospital in Vancouver, BC. Dr Chung and Dr Cheng are members and Dr Goldman is Director of the PRETx program. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875-2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    BakerSSLiptakGSCollettiRBCroffieJMDi LorenzoCEctorWConstipation in infants and children: evaluation and treatment. A medical position statement of the North American Society for Pediatric Gastroenterology and NutritionJ Pediatr Gastroenterol Nutr199929561226
    OpenUrlCrossRefPubMed
  2. ↵
    FeltBBrownPCoranAKochharPOpipari-ArriganLFunctional constipation and soiling in childrenAnn Arbor, MIRegents of the University of Michigan2003Available from: http://cme.med.umich.edu/pdf/guideline/peds03.pdfAccessed 2009 Jan 24
  3. ↵
    BiggsWSDeryWHEvaluation and treatment of constipation in infants and childrenAm Fam Physician200673346977
    OpenUrlPubMed
  4. ↵
    YoussefNNPetersJMHendersonWShultz-PetersSLockhartDKDi LorenzoCDose response of PEG 3350 for the treatment of childhood fecal impactionJ Pediatr200214134104
    OpenUrlCrossRefPubMed
  5. ↵
    Loening-BauckeVKrishnaRPashankarDSPolyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlersJ Pediatr Gastroenterol Nutr20043955369
    OpenUrlPubMed
  6. ↵
    PashankarDSBishopWPLoening-BauckeVLong-term efficacy of polyethylene glycol 3350 for the treatment of chronic constipation in children with and without encopresisClin Pediatr (Phila)20034298159
    OpenUrlAbstract/FREE Full Text
  7. ↵
    GremseDAHixonJCrutchfieldAComparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation in childrenClin Pediatr (Phila)20024142259
    OpenUrlAbstract/FREE Full Text
  8. ↵
    PashankarDSLoening-BauckeVBishopWPSafety of polyethylene glycol 3350 for the treatment of chronic constipation in childrenArch Pediatr Adolesc Med200315776614
    OpenUrlCrossRefPubMed
  9. ↵
    NurkoSYoussefNNSabriMLangsederAMcGowanJClevelandMPEG3350 in the treatment of childhood constipation: a multicenter, double-blinded, placebo-controlled trialJ Pediatr2008153225461261.e1Epub 2008 Mar 19
    OpenUrlCrossRefPubMed
  10. ↵
    Loening-BauckeVPashankarDSA randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinencePediatrics2006118252835
    OpenUrlAbstract/FREE Full Text
  11. ↵
    PashankarDSBishopWPEfficacy and optimal dosing of daily polyethylene glycol 3350 for treatment of constipation and encopresis in childrenJ Pediatr2001139342832
    OpenUrlCrossRefPubMed
  12. ↵
    BellEAWallGCPediatric constipation therapy using guidelines and polyethylene glycol 3350Ann Pharmacother200438468693Epub 2004 Feb 27
    OpenUrlCrossRefPubMed
  13. ↵
    AroraRSrinivasanRIs polyethylene glycol safe and effective for chronic constipation in children?Arch Dis Child20059066436
    OpenUrlFREE Full Text
  14. ↵
    Loening-BauckeVPrevalence, symptoms and outcome of constipation in infants and toddlersJ Pediatr2005146335963
    OpenUrlCrossRefPubMed
  15. ↵
    MichailSGendyEPreud’HommeDMezoffAPolyethylene glycol for constipation in children younger than eighteen months oldJ Pediatr Gastroenterol Nutr20043921979
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 55 (5)
Canadian Family Physician
Vol. 55, Issue 5
1 May 2009
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Polyethylene glycol 3350 without electrolytes for treatment of childhood constipation
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Polyethylene glycol 3350 without electrolytes for treatment of childhood constipation
Seen Chung, Adam Cheng, Ran D. Goldman
Canadian Family Physician May 2009, 55 (5) 481-482;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Polyethylene glycol 3350 without electrolytes for treatment of childhood constipation
Seen Chung, Adam Cheng, Ran D. Goldman
Canadian Family Physician May 2009, 55 (5) 481-482;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Disimpaction
    • Maintenance and treatment
    • Safety
    • Infants and toddlers
    • Conclusion
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Child Health Update

  • Accidental cannabis ingestion in young children
  • All-terrain vehicle injuries in children and adolescents
  • Screen time and sleep in children
Show more Child Health Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire